An interesting case of seronegative neuro myelitis optica spectrum disorder
DOI:
https://doi.org/10.18203/2349-3933.ijam20230070Keywords:
Seronegative neuromyelitis optica, Optic neuritis, Aquaporin-4 IgG antibodiesAbstract
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes severe demyelination, especially in the optic nerve and spinal cord with typical clinical manifestations of acute optic neuritis and transverse myelitis. Seventy to ninety percent of the cases of NMOSD test positive for aquaporin 4 IgG Antibodies (AQP4 IgG Ab). Here we report a case of 22-year-old female who presented with history of diffuse headache since 1 week, history of double vision since1 week and excessive day time sleepiness since2 months. Patient had a past history of bilateral and simultaneous optic neuritis 9 months back. On further evaluation patient was diagnosed as seronegative NMOSD (AQP4 IgG Ab–negative).
References
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89.
Alshurafa ZH, Alkhateeb MO. Seronegative Neuromyelitis Optica Spectrum Disorder: An Unusual Presentation of Acute Brainstem Syndrome. Am J Case Rep. 2020;21:e922590.
Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019;32(3):385-94.
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501.
Alshurafa ZH, Alkhateeb MO. Seronegative Neuromyelitis Optica Spectrum Disorder: An Unusual Presentation of Acute Brainstem Syndrome. Am J Case Rep. 2020;21:e922590.
Khadka B, Bhattarai AM, Dhakal B, Karki A, Acharya A, Poudel R. Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report, Ann Med Surg. 2022;78:103757.
Gibbons E, Campgana G, O’Connell K, Yeo T, Whittam D, Karthikeayan VM, et al. What is seronegative neuromyelitis optica spectrum disorder? J Neurol Neurosurg Psychiatry. 2022;93:A34.
Dauby S, Dive D, Lutteri L, Andris C, Hansen I, Maquet P, Lommers E. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Acta Neurol Belg. 2022;122(1):135-44.
Hyun JW, Kim Y, Kim KH, Kim SH, Olesen MN, Asgari N, Siritho S, Paul F, Kim HJ. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. J Neuroinflammation. 2022;19(1):86.
Etemadifar M, Nouri H, Khorvash R, Salari M, Ghafari K, Aghababaee A. Frequency of diencephalic syndrome in NMOSD. Acta Neurol Belg. 2022;122(4):961-7.
Carlander B, Vincent T, Le Floch A, Pageot N, Camu W, Dauvilliers Y, et al. Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes. J Neurol Neurosurg Psychiatry. 2008;79:333-4.
Poppe AY, Lapierre Y, Melançon D, Lowden D, Wardell L, Fullerton LM, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler. 2005;11:617-21.
Waliszewska-Prosół M, Chojdak-Łukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects. Int J Mol Sci. 2021;22(6):2801.
Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019;19(2):169-76.
